AbbVie (ABBV) Accounts Payables (2012 - 2026)
AbbVie (ABBV) reported Accounts Payables of $33.8 billion for Q1 2026, up 8.8% year-over-year from $31.0 billion in Q1 2025, and down 2.76% on a QoQ basis from $34.7 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Accounts Payables data on file, last reported at $33.8 billion in Q1 2026.
- Quarterly Accounts Payables rose 8.8% year-over-year to $33.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.8 billion (up 8.8% YoY) and the FY2025 annual result came in at $34.7 billion, up 8.73% from the prior year.
- Accounts Payables declined to $33.8 billion in Q1 2026 per ABBV's latest filing, from $34.7 billion in the prior quarter.
- Across five years, Accounts Payables topped out at $34.7 billion in Q4 2025 and bottomed at $22.5 billion in Q2 2022.
- The 5-year median for Accounts Payables is $30.5 billion (2024), against an average of $29.1 billion.
- The widest annual swing landed in 2024, when Accounts Payables increased 26.37%; it then fell 0.91% in 2025.
- Tracing ABBV's Accounts Payables over 5 years: stood at $25.4 billion in 2022, then climbed by 20.66% to $30.6 billion in 2023, then climbed by 4.23% to $31.9 billion in 2024, then rose by 8.73% to $34.7 billion in 2025, then declined by 2.76% to $33.8 billion in 2026.
- Per Business Quant, the three latest ABBV Accounts Payables figures stand at $33.8 billion (Q1 2026), $34.7 billion (Q4 2025), and $33.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 10.46 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 3.86 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 20.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.77 Bn |
| Dec 31, 2025 | 34.73 Bn |
| Sep 30, 2025 | 33.62 Bn |
| Jun 30, 2025 | 32.25 Bn |
| Mar 31, 2025 | 31.04 Bn |
| Dec 31, 2024 | 31.95 Bn |
| Sep 30, 2024 | 30.49 Bn |
| Jun 30, 2024 | 29.33 Bn |
| Mar 31, 2024 | 31.33 Bn |
| Dec 31, 2023 | 30.65 Bn |
| Sep 30, 2023 | 29.66 Bn |
| Jun 30, 2023 | 27.04 Bn |
| Mar 31, 2023 | 24.79 Bn |
| Dec 31, 2022 | 25.40 Bn |
| Sep 30, 2022 | 23.51 Bn |
| Jun 30, 2022 | 22.54 Bn |
| Mar 31, 2022 | 22.57 Bn |
| Dec 31, 2021 | 22.70 Bn |
| Sep 30, 2021 | 21.86 Bn |
| Jun 30, 2021 | 20.78 Bn |
| Mar 31, 2021 | 20.60 Bn |
| Dec 31, 2020 | 20.16 Bn |
| Sep 30, 2020 | 19.40 Bn |
| Jun 30, 2020 | 19.28 Bn |
| Mar 31, 2020 | 12.71 Bn |
| Dec 31, 2019 | 11.83 Bn |
| Sep 30, 2019 | 12.22 Bn |
| Jun 30, 2019 | 11.30 Bn |
| Mar 31, 2019 | 11.83 Bn |
| Dec 31, 2018 | 11.93 Bn |
| Sep 30, 2018 | 11.37 Bn |
| Jun 30, 2018 | 10.69 Bn |
| Mar 31, 2018 | 10.68 Bn |
| Dec 31, 2017 | 10.23 Bn |
| Sep 30, 2017 | 9.21 Bn |
| Jun 30, 2017 | 8.84 Bn |
| Mar 31, 2017 | 8.42 Bn |
| Dec 31, 2016 | 9.38 Bn |
| Sep 30, 2016 | 9.08 Bn |
| Jun 30, 2016 | 8.76 Bn |
| Mar 31, 2016 | 8.24 Bn |
| Dec 31, 2015 | 8.46 Bn |
| Sep 30, 2015 | 8.05 Bn |
| Jun 30, 2015 | 7.25 Bn |
| Mar 31, 2015 | 6.46 Bn |
| Dec 31, 2014 | 1.40 Bn |
| Sep 30, 2014 | 6.31 Bn |
| Jun 30, 2014 | 6.05 Bn |
| Mar 31, 2014 | 6.20 Bn |
| Dec 31, 2013 | 933.00 Mn |
| Sep 30, 2013 | 6.44 Bn |
| Jun 30, 2013 | 6.37 Bn |
| Mar 31, 2013 | 6.33 Bn |
| Dec 31, 2012 | 5.73 Bn |